Literature DB >> 10590325

HPV6b virus like particles are potent immunogens without adjuvant in man.

L F Zhang1, J Zhou, S Chen, L L Cai, Q Y Bao, F Y Zheng, J Q Lu, J Padmanabha, K Hengst, K Malcolm, I H Frazer.   

Abstract

Subjects with genital warts were immunized three times or more with HPV6b VLPs without adjuvant. All immunized subjects had DTH to HPV6b L1 protein. Of 32 subjects, nine had HPV6b specific antibody prior to immunization and 22 acquired antibody with immunization. VLP specific antibody increased following a single immunization in 6 of 8 subjects with low level antibody at recruitment. Complete regression of genital warts was observed in 25 of 33 evaluable subjects over the 20-week observation period. We conclude that immunization with HPV6b L1 VLPs without adjuvant induces immunity to the L1 protein epitopes recognised during natural infection, and may accelerate regression of warts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590325     DOI: 10.1016/s0264-410x(99)00351-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  Does human papillomavirus cause pterygium?

Authors:  T W Reid; N Dushku
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

Review 2.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

3.  Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study.

Authors:  T Kohl; I I Hitzeroth; D Stewart; A Varsani; V A Govan; N D Christensen; A-L Williamson; E P Rybicki
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice.

Authors:  Zhong-Hua Deng; Ye-Xia Hao; Li-Hong Yao; Zhi-Ping Xie; Han-Chun Gao; Le-Yun Xie; Li-li Zhong; Bing Zhang; You-De Cao; Zhao-Jun Duan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

5.  A multimeric L2 vaccine for prevention of animal papillomavirus infections.

Authors:  Subhashini Jagu; Nicole Malandro; Kihyuck Kwak; Hang Yuan; Richard Schlegel; Kenneth E Palmer; Warner K Huh; M Saveria Campo; Richard B S Roden
Journal:  Virology       Date:  2011-09-13       Impact factor: 3.616

6.  The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.

Authors:  Weili Yan; Leaf Huang
Journal:  Int J Pharm       Date:  2008-10-15       Impact factor: 5.875

7.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

Authors:  Balasubramanyam Karanam; Ratish Gambhira; Shiwen Peng; Subhashini Jagu; Dae-Jin Kim; Gary W Ketner; Peter L Stern; Robert J Adams; Richard B S Roden
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

10.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.